Biogen Inc. (BIIB) Q3 2016 Earnings Results

Biogen Beats on EPS, Stock Up 3.66%

Biogen's earnings report shows a solid performance in terms of EPS, which exceeded expectations, contributing to a positive stock reaction of 3.66%. The company did not provide revenue figures or future guidance, leaving some uncertainty for investors. The management's focus on their product pipeline and R&D suggests they are positioning for growth, but the lack of detailed guidance may lead to cautious sentiment among investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$5.19	N/A	+3.80%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their current projects and market position. However, they did not provide specific guidance for future quarters.

Management highlighted strong performance in key therapeutic areas.

They emphasized ongoing commitment to research and development.

The team expressed confidence in future product pipeline.

Biogen Beats on EPS, Stock Up 3.66%

Key numbers

Management commentary

Biogen Inc.

More earnings this week

Biogen Beats on EPS, Stock Up 3.66%

Key numbers

Management commentary